Evogliptin (INN; trade names Suganon, Evodine) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs.[1] It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea[2] and Russia.[3] In a meta-analysis involving data from 6 randomized controlled trials (887 patients), Dutta et. al. demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and linagliptin. [4]
^McCormack PL (November 2015). "Evogliptin: First Global Approval". Drugs. 75 (17): 2045–9. doi:10.1007/s40265-015-0496-5. PMID 26541763. S2CID 46450821.
^. pipelinereview.com. October 2, 2015. Archived from the original on June 30, 2022. Retrieved February 1, 2017.
^"Evodine (evogliptin) film-coated tablets. Full prescribing information". Russian State Register of Medicines (in Russian).
^Dutta D, Bhattacharya S, Krishnamurthy A, Sharma LK, Sharma M (Nov 2020). "Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis". Indian J Endocrinol Metab. 24 (5): 434–445. doi:10.4103/ijem.IJEM_418_20. PMC7810058. PMID 33489850.
evogliptin, trade, names, suganon, evodine, antidiabetic, drug, dipeptidyl, peptidase, inhibitor, gliptin, class, drugs, developed, south, korean, pharmaceutical, company, dong, approved, south, korea, russia, meta, analysis, involving, data, from, randomized,. Evogliptin INN trade names Suganon Evodine is an antidiabetic drug in the dipeptidyl peptidase 4 DPP 4 inhibitor or gliptin class of drugs 1 It was developed by the South Korean pharmaceutical company Dong A ST and is approved for use in South Korea 2 and Russia 3 In a meta analysis involving data from 6 randomized controlled trials 887 patients Dutta et al demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and linagliptin 4 EvogliptinClinical dataTrade namesSuganonOther namesDA 1229Routes ofadministrationBy mouthATC codeA10BH07 WHO IdentifiersIUPAC name 3R 4 3R 3 Amino 4 2 4 5 trifluorophenyl butanoyl 3 2 methyl 2 propanyl oxy methyl 2 piperazinoneCAS Number1222102 29 5PubChem CID25022354ChemSpider26339341UNII09118300L7KEGGD11023ChEMBLChEMBL1779710CompTox Dashboard EPA DTXSID00153545Chemical and physical dataFormulaC 19H 26F 3N 3O 3Molar mass401 430 g mol 13D model JSmol Interactive imageSMILES CC C C OC C H 1C O NCCN1C O C C H Cc2cc c cc2F F F NInChI InChI 1S C19H26F3N3O3 c1 19 2 3 28 10 16 18 27 24 4 5 25 16 17 26 8 12 23 6 11 7 14 21 15 22 9 13 11 20 h7 9 12 16H 4 6 8 10 23H2 1 3H3 H 24 27 t12 16 m1 s1Key LCDDAGSJHKEABN MLGOLLRUSA NReferences edit McCormack PL November 2015 Evogliptin First Global Approval Drugs 75 17 2045 9 doi 10 1007 s40265 015 0496 5 PMID 26541763 S2CID 46450821 Dong A ST s DPP4 inhibitor SUGANON got approved for type 2 diabetes in Korea pipelinereview com October 2 2015 Archived from the original on June 30 2022 Retrieved February 1 2017 Evodine evogliptin film coated tablets Full prescribing information Russian State Register of Medicines in Russian Dutta D Bhattacharya S Krishnamurthy A Sharma LK Sharma M Nov 2020 Efficacy and Safety of Novel Dipeptidyl Peptidase 4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus A Meta Analysis Indian J Endocrinol Metab 24 5 434 445 doi 10 4103 ijem IJEM 418 20 PMC 7810058 PMID 33489850 nbsp This drug article relating to the gastrointestinal system is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Evogliptin amp oldid 1215013624, wikipedia, wiki, book, books, library,
